NVS Stock: Price, Earnings History and SEC Filings
Novartis AG (NVS) last traded at $160.79, down 0.19% on the latest session and up 12.8% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $2.46 against an analyst estimate of $2.25, a beat of 9.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NVS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 27, 2026 | $2.46 | $2.25 | +9.33% |
| Jun 2026 | Jul 21, 2026 | $2.41 | $2.20 | +9.55% |
| Mar 2026 | Apr 28, 2026 | $1.99 | $2.11 | -5.69% |
| Dec 2025 | Feb 4, 2026 | $2.03 | $1.99 | +2.01% |
NVS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NVS
Insider filing activity
NVS insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NVS news
- St. Galler Kantonalbank (SWX:SGKN) Stock Looks Reasonable With Moderate Excess ReturnsNov 1, 2026 · finance.yahoo.com
- Novartis stock heads into Boston advanced-therapies eventNov 1, 2026 · ad-hoc-news.de
- 3 Oil Stocks Investors Are Screening As Brent Forecasts Move HigherOct 31, 2026 · finance.yahoo.com
- French Bank Stocks Under Pressure After Fitch WarningOct 31, 2026 · finance.yahoo.com
- Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced ApproachOct 31, 2026 · seekingalpha.com
- All You Need to Know About Novartis (NVS) Rating Upgrade to BuyOct 30, 2026 · finance.yahoo.com
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered CapsidsOct 30, 2026 · finance.yahoo.com
- Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA DeliveryOct 30, 2026 · finance.yahoo.com
About Novartis AG
Novartis AG (NVS) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Switzerland. Its fiscal year ends in December.